about
Nintedanib in NSCLC: evidence to date and place in therapyNew findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsAnalysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus.Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.Monoclonal antibodies in gastrointestinal cancers.Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.Ramucirumab and its use in gastric cancer treatment.Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy.Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis.Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.Dietary restriction: could it be considered as speed bump on tumor progression road?The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy.Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study.Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis.Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer.Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer.The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysisReal life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II studyPublisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysisMonitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patientsAnalysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variationsMolecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potentialThe use of SAMe in chemotherapy-induced liver injuryAn update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapyAre Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trialsDenosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trialsHow to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis
P50
Q26745424-5FF025C5-8E77-41B6-8940-773FBCFBDE5DQ26796348-92503253-9662-47DA-99CC-8E5364D25374Q27853353-39BC0167-6B7D-4ED1-A66E-699FFC79C3E4Q28546769-95F97A81-627C-48CC-940D-BD3CDC42052BQ33618910-249FD6AB-E87F-4662-A66C-491F4D9D4356Q37565288-56CC2122-445C-463B-9A8B-999224CEE04DQ37645090-4C5687BE-1F94-4B78-89FF-D4407684BAA0Q38084684-5B21BC1C-3B66-4B3D-85D3-4BF457C9FC16Q38253815-B6055C39-6906-4D00-A9BD-48E21C2D188CQ38260034-677677DF-F2D4-48E2-9EFD-1A72AF18A749Q38264378-FD58D77F-2B2E-44FE-8095-127B9D6EF8B1Q38340168-A43500AA-803D-4A16-BFD6-9FB18A93DB26Q38699358-9A71AF2B-EC3F-40A2-B96B-091AE10EE4D6Q38797885-E5895729-4C28-4F8B-A95D-8F8113B74576Q39002572-DAE5A376-3AAA-4973-B4C1-51532E3D7074Q41044367-9177E83A-C2B8-4BD0-8A23-3A82058A9EAAQ48110081-20249F95-FC35-40C4-AE44-DBADC484C28FQ50872393-B8E6F5A4-2776-4F33-8A1D-CF2B32F0326FQ52943599-189E4199-ED8C-4225-88A0-38FAFB964B42Q53703482-1D4F3C93-C0C2-455B-801F-E2F713AEA8BCQ55155589-17AA30BD-BE8E-449B-AB92-41D5D0736ABAQ55241291-41B02CB6-ADD1-4019-B08E-E8AEAED631C7Q58761975-3059E056-ADF1-4940-94CA-21429FA9838AQ58796906-559987E0-7ABD-416D-8C9B-8107150AA2D9Q59335739-66A7E1A4-B113-40ED-A36A-48F80F90C4A4Q64111039-A1C5EB2F-4B08-4B87-A8C6-14F63EAF6CC8Q86703969-EE3CA6B2-6BCA-4257-9D03-E6B18B5DFF41Q88305519-182FA038-9D6A-4962-A327-3CC5941B75E8Q91344752-BD6CABC6-D6B4-4D0F-99F9-7E885A2C4E46Q91817890-6EE5A539-F742-483D-99B7-801227A072D6Q91894394-27236E38-E1D7-468D-B9B3-79B12B4F5756Q92387728-E4235526-E6F7-4B33-8DA2-F40C1C2A5A51Q92801810-3D543ADE-BD5E-4232-ACBF-6E885EE735E8Q92824618-DA521C6D-07D3-4D2B-9AA9-A03295176B64
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Antonio Galvano
@en
Antonio Galvano
@nl
type
label
Antonio Galvano
@en
Antonio Galvano
@nl
prefLabel
Antonio Galvano
@en
Antonio Galvano
@nl
P31
P496
0000-0003-4365-5683